Targeted ADCs vs Chemotherapy in Heavily Pretreated NSCLC: Clinical Benefits and Challenges

Author(s):

Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center,Christine Bestvina, MD, University of Chicago

This episode discusses the urgent need for more effective and tolerable therapies for patients with EGFR-mutated NSCLC who have exhausted targeted treatments, comparing the clinical benefits of a targeted ADC approach vs chemotherapy, with a focus on the TROPION-Lung01 study of Dato-DXd vs docetaxel for heavily pretreated advanced/metastatic NSCLC with actionable genomic alterations.

EP: 1.Clinical Insights on Osimertinib in Frontline Therapy for EGFR-Mutated NSCLC

EP: 2.Optimizing Treatment for Advanced EGFR-Mutated NSCLC: FLAURA2, Toxicity Management, and ctDNA

EP: 3.ADAURA Trial Findings: Outcomes and CNS Involvement in EGFR-Mutated NSCLC

EP: 4.Osimertinib in Resected Stage IB to IIIA NSCLC: Perspectives on Its Use for Less Common EGFR Mutations

EP: 5.Tailoring Treatment by Stage: Insights From ADAURA for Stage IB to IIIA EGFR-Mutated NSCLC

Now Viewing

EP: 6.Targeted ADCs vs Chemotherapy in Heavily Pretreated NSCLC: Clinical Benefits and Challenges

Video content above is prompted by the following:

Please briefly discuss the urgent need for more effective and tolerable therapies for patients with EGFR-mutated NSCLC who have exhausted available, targeted therapies.
What are the clinical benefits of a targeted ADC approach vs chemotherapy for heavily pretreated advanced/metastatic NSCLC?